KeynoteSolid Tumors

Explore an Investigational Immunotherapy Trial for Solid Tumors

As the sponsor of the Keynote Oncology Clinical Trials, Merck is passionate about improving health. We are committed to accelerating every step in the journey in our quest to bring treatment options to people with cancer.

Pembrolizumab has been FDA-approved for use in certain types of cancer.

To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.


Active Trials


Trials Recruiting


US Trial Locations

Explore Active Clinical Trials

Trial Description Keynote Trial Condition Phase Status
keynote study logo Study of Pembrolizumab in Participants With Advanced Solid Tumors 158 Advanced Cancer Phase 2 Recruiting